Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 83-90

  Oshibuchi, Hidehiro ^a   Inada, Ken ^a   Sugawara, Hiroko ^a   Ishigooka, Jun ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Amygdala; Antipsychotic agent; Aripiprazole; Dopamine; Fear conditioning; Haloperidol; In vivo microdialysis; Methamphetamine

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; METHAMPHETAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMOTIONAL STRESS; FEAR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

AMYGDALA; ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING (PSYCHOLOGY); DOPAMINE; ELECTRIC STIMULATION; FEAR; HALOPERIDOL; MALE; METHAMPHETAMINE; MICRODIALYSIS; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; STRESS, PSYCHOLOGICAL;

EID: 67449126646     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.05.006     Document Type: Article

References (50)

1. Adell A., Casanovas J.M., and Artigas F. Comparative study in the rat of the actions of different types of stress on the release of 5-HT in raphe nuclei and forebrain areas. Neuropharmacology 36 (1997) 735-741
2. Amat J., Matus A.P., Watkins L.R., and Maier S.F. Escapable and inescapable stress differentially alter extracellular levels of 5-HT in the basolateral amygdala of the rat. Brain Res. 812 (1998) 113-120
3. Asan E. The catecholaminergic innervation of the rat amygdala. Adv. Anat. Embryol. Cell Biol. 142 (1998) 1-118
4. Aubert I., Brana C., Pellevoisin C., Giros B., Caille I., Carles D., Vital C., and Bloch B. Molecular anatomy of the development of the human substantia nigra. J. Comp. Neurol. 379 (1997) 72-87
5. Bissiere S., Humeau Y., and Luthi A. Dopamine gates LTP induction in lateral amygdala by suppressing feedforward inhibition. Nat. Neurosci. 6 (2003) 587-592
6. Borowski T.B., and Kokkinidis L. The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav. Neurosci. 112 (1998) 952-965
7. Bortolozzi A., Diaz-Mataix L., Toth M., Celada P., and Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl.) 191 (2007) 745-758
8. Brinley R.M., and McDonald A.J. Evidence that dopaminergic axons provide a dense innervation of specific neuronal subpopulations in the rat basolateral amygdala. Brain Res. 850 (1999) 127-135
9. Chen N.N., and Pan W.H. Regulatory effects of D2 receptors in the ventral tegmental area on the mesocorticolimbic dopaminergic pathway. J. Neurochem. 74 (2000) 2576-2582
10. de Groote L., and Linthorst A.C. Exposure to novelty and forced swimming evoke stressor-dependent changes in extracellular GABA in the rat hippocampus. Neuroscience 148 (2007) 794-805
11. Debiec J., and LeDoux J.E. Noradrenergic signaling in the amygdala contributes to the reconsolidation of fear memory: treatment implications for PTSD. Ann. N. Y. Acad. Sci. 1071 (2006) 521-524
12. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., and Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. N. Y. Acad. Sci. 877 (1999) 412-438
13. Fallon J.H., and Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180 (1978) 545-580
14. Fanselow M.S. Conditioned and unconditional components of post-shock freezing. Pavlovian J. Biol. Sci. 15 (1980) 177-182
15. Finlay J.M., and Zigmond M.J. The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem. Res. 22 (1997) 1387-1394
16. Greba Q., Gifkins A., and Kokkinidis L. Inhibition of amygdaloid dopamine D2 receptors impairs emotional learning measured with fear-potentiated startle. Brain Res. 899 (2001) 218-226
17. Guarraci F.A., Frohardt R.J., Falls W.A., and Kapp B.S. The effects of intra-amygdaloid infusions of a D2 dopamine receptor antagonist on Pavlovian fear conditioning. Behav. Neurosci. 114 (2000) 647-651
18. Hashimoto S., Inoue T., Muraki I., and Koyama T. Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009) 113-117
19. Inglis F.M., and Moghaddam B. Dopaminergic innervation of the amygdala is highly responsive to stress. J. Neurochem. 72 (1999) 1088-1094
20. Inoue T. Effects of conditioned fear stress on monoaminergic systems in the rat brain. Hokkaido Igaku Zasshi 68 (1993) 377-390
21. Inoue T., Tsuchiya K., and Koyama T. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol. Biochem. Behav. 55 (1996) 195-201
22. Inoue T., Izumi T., Maki Y., Muraki I., and Koyama T. Effect of the dopamine D(1/5) antagonist SCH 23390 on the acquisition of conditioned fear. Pharmacol. Biochem. Behav. 66 (2000) 573-578
23. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18 (1993) 75-113
24. Kalivas P.W., and Duffy P. A comparison of axonal and somatodendritic dopamine release using in vivo dialysis. J. Neurochem. 56 (1991) 961-967
25. Karler R., Chaudhry I.A., Calder L.D., and Turkanis S.A. Amphetamine behavioral sensitization and the excitatory amino acids. Brain Res. 537 (1990) 76-82
26. LeDoux J.E. Emotional memory: in search of systems and synapses. Ann. N. Y. Acad. Sci. 702 (1993) 149-157
27. LeDoux J.E. Emotional memory systems in the brain. Behav. Brain Res. 58 (1993) 69-79
28. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493 (2004) 75-83
29. Li Z., Ichikawa J., Huang M., Prus A.J., Dai J., and Meltzer H.Y. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl.) 183 (2005) 144-153
30. Lysaker P.H., and Salyers M.P. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr. Scand. 116 (2007) 290-298
31. Marowsky A., Yanagawa Y., Obata K., and Vogt K.E. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron 48 (2005) 1025-1037
32. Matsumoto M., Togashi H., Kaku A., Kanno M., Tahara K., and Yoshioka M. Cortical GABAergic regulation of dopaminergic responses to psychological stress in the rat dorsolateral striatum. Synapse 56 (2005) 117-121
33. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
34. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., and Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 79 (1997) 323-327
35. Muraki I. Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate. Hokkaido Igaku Zasshi 76 (2001) 57-70
36. Nader K., and LeDoux J. The dopaminergic modulation of fear: quinpirole impairs the recall of emotional memories in rats. Behav. Neurosci. 113 (1999) 152-165
37. Oades R.D., and Halliday G.M. Ventral tegmental (A10) system: neurobiology. 1. Anatomy. and. connectivity. Brain Res. 434 (1987) 117-165
38. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates, compact third ed (1997), Academic Press, San Diego
39. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396 (1986) 157-198
40. Sato M., Numachi Y., and Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr. Bull. 18 (1992) 115-122
41. Seiden L.S., Sabol K.E., and Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 639-677
42. Selemon L.D., Begovic A., Goldman-Rakic P.S., and Castner S.A. Amphetamine sensitization alters dendritic morphology in prefrontal cortical pyramidal neurons in the non-human primate. Neuropsychopharmacology 32 (2007) 919-931
43. Simmons D.A., Brooks B.M., and Neill D.B. GABAergic inactivation of basolateral amygdala alters behavioral processes other than primary reward of ventral tegmental self-stimulation. Behav. Brain Res. 181 (2007) 110-117
44. Stork O., Ji F.Y., and Obata K. Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a conditioned fear stimulus. Neurosci. Lett. 327 (2002) 138-142
45. Suzuki T., Ishigooka J., Watanabe S., and Miyaoka H. Enhancement of delayed release of dopamine in the amygdala induced by conditioned fear stress in methamphetamine-sensitized rats. Eur. J. Pharmacol. 435 (2002) 59-65
46. Tanaka T., Ishigooka J., Watanabe S., Nagata E., and Miura S. Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in methamphetamine-sensitized rat. Nihon Shinkei Seishin Yakurigaku Zasshi 18 (1998) 1-7
47. Tanaka M., Yoshida M., Emoto H., and Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur. J. Pharmacol. 405 (2000) 397-406
48. Tenn C.C., Kapur S., and Fletcher P.J. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berl.) 180 (2005) 366-376
49. Westerink B.H., Kwint H.F., and deVries J.B. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J. Neurosci. 16 (1996) 2605-2611
50. Wetherell J.L., Palmer B.W., Thorp S.R., Patterson T.L., Golshan S., and Jeste D.V. Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 64 (2003) 1476-1482